You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 5, May 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy

Esther H. Chang, PhD; Yng-Ju Jang, MSc; Zhengmei Hao; Gloria Murphy, MSc; Antonina Rait, PhD; Willard E. Fee, Jr, MD; Howard H. Sussman, MD; Patricia Ryan, PhD; Yawen Chiang, PhD; Kathleen F. Pirollo, PhD

Arch Otolaryngol Head Neck Surg. 1997;123(5):507-512.


Abstract

Background
A significant number of squamous cell carcinomas of the head and neck (SCCHN) resist radiation treatment, the most common form of adjuvant therapy for this disease. The presence of a mutant form of the tumor suppressor gene p53 has been correlated with disruption of programmed cell death (apoptosis) and reduced cell cycle arrest, resulting in increased radiation resistance and survival.

Methods and Results
We introduced by means of an adenoviral vector a functional p53 gene into a radiation-resistant SCCHN cell line that harbors mutant p53. Replacement of wild-type p53 restored the G1 block and apoptosis in these cells in vitro. Moreover, introduction of wild-type p53 sensitized SCCHN-induced mouse xenografts to radiotherapy in vivo.

Conclusion
The combination of p53 replacement gene therapy with conventional radiotherapy may treat SCCHN more effectively.

Arch Otolaryngol Head Neck Surg. 1997;123:507-512



Author Affiliations

From the Division of Otolaryngology, Department of Surgery (Drs Chang, Jang, Rait, Fee, and Pirollo and Ms Hao), and the Department of Pathology (Ms Murphy and Dr Sussman), Stanford University, Stanford, Calif; and Genetic Therapy Incorporated/Sandoz, Gaithersburg, Md (Drs Ryan and Chiang). Drs Chang, Rait, and Pirollo are now with the Department of Otolaryngology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Evolving Role of Combined Modality Therapy in Head and Neck Cancer
Robbins
Arch Otolaryngol Head Neck Surg 2000;126:265-269.
FULL TEXT  

Human Endothelial Cell Life Extension by Telomerase Expression
Yang et al.
J. Biol. Chem. 1999;274:26141-26148.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.